On September 6, 2019 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported that its Chief Executive Officer, Jed Latkin, will present a corporate overview of the Company at the H.C. Wainwright 21st Annual Global Investment Conference, being held September 8-10, 2019 in New York, New York (Press release, Navidea Biopharmaceuticals, SEP 6, 2019, https://ir.navidea.com/news/detail/326/navidea-biopharmaceuticals-to-present-at-the-h-c-wainwright-21st-annual-global-investment-conference [SID1234539340]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conference Presentation Details
When:
September 9, 2019, 3:50-4:15 p.m.
Where:
Lotte New York Palace Hotel
Room:
Holmes II (4th floor)
Webcast Link:
A replay of the webcast will be available for 90 days.